Boehringer Ingelheim is to work with Pantheon to develop two projects worth over $18 million involving combination drugs to treat type II diabetes.
Mark Kontny, Chief Scientific Officer at Pantheon, said: “I am very gratified that Boehringer Ingelheim recognises our expertise in formulating, scaling and successfully launching complex formulations such as these molecules. It is this kind of support and recognition that has enabled us to develop our market leading position in pharmaceutical development services.”
The projects are set to span over a three year period.
Patheon is a global provider of pharmaceutical services, manufacturing at ten facilities and nine development centres across North America and Europe.